Get startedLog in
    Picture of Crispr Therapeutics AG logo

    CRSP — Crispr Therapeutics AG News Story

    0.000.00%
    us flag iconLast trade - 00:00
    HealthcareAdventurousLarge CapMomentum Trap
    All News

    Brief: CRISPR Therapeutics Announces U.S. FDA Approval of CASGEVY (exagamglogene autotemcel) For The Treatment of Transfusion-Dependent Beta Thalassemia

    Picture of Crispr Therapeutics AG logoCrispr Therapeutics AG
    16/01/2024 21:42
    Jan 16 (Reuters) - CRISPR Therapeutics AG  CRSP.BN :
    * CRISPR THERAPEUTICS ANNOUNCES U.S. FOOD AND DRUG
ADMINISTRATION
(FDA) APPROVAL OF CASGEVY™ (EXAGAMGLOGENE AUTOTEMCEL) FOR THE
TREATMENT OF TRANSFUSION-DEPENDENT BETA THALASSEMIA

Source text for Eikon:  ID:nGNX1dSQm 
Further company coverage:  CRSP.BN 

 ((Reuters.Briefs@thomsonreuters.com;))

    Recent news on Crispr Therapeutics AG

    See all news